Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network

Silvia Stacchiotti, Noemi Simeone, Salvatore Lo Vullo, Giacomo G Baldi, Antonella Brunello, Bruno Vincenzi, Elena Palassini, GianPaolo Dagrada, Paola Collini, Carlo Morosi, Francesca G Greco, Marta Sbaraglia, Angelo P Dei Tos, Luigi Mariani, Anna Maria Frezza, Paolo G Casali, Silvia Stacchiotti, Noemi Simeone, Salvatore Lo Vullo, Giacomo G Baldi, Antonella Brunello, Bruno Vincenzi, Elena Palassini, GianPaolo Dagrada, Paola Collini, Carlo Morosi, Francesca G Greco, Marta Sbaraglia, Angelo P Dei Tos, Luigi Mariani, Anna Maria Frezza, Paolo G Casali

Abstract

Background: The objective of this study was to report on a retrospective series of patients with epithelioid hemangioendothelioma (EHE) who received treatment with sirolimus within the Italian Rare Cancer Network.

Methods: From January 2005, 38 adult patients with advanced EHE received continuous-dosing sirolimus, 5 mg daily, until they developed either toxicity or disease progression. Disease progression in the 6 months before the start of treatment was required. Each pathologic diagnosis was reviewed. The daily dose of sirolimus was adjusted based on plasma levels. Response was retrospectively assessed by local investigators using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST). Survival was estimated using the Kaplan-Meier method.

Results: All 38 patients (WW Domain Containing Transcription Regulator 1 [WWTR1]-positive, n = 37; transcription factor E3 [TFE3]-positive, n = 1) had disease progression before starting sirolimus (at baseline, 13 of 38 patients had the presence of serosal effusions and systemic symptoms). Thirty-seven patients were evaluable for response (there was 1 early interruption). The best RECIST responses were a partial response in 4 patients (10.8%), stable disease in 28 patients (75.7%), and disease progression in 5 patients (13.5%). At a 41.5-month median follow-up (interquartile range [IQR], 23.9-56.8 months), the median PFS was 13 months (95% CI, 3.7 months to not estimated [NE]), and the median OS was 18.8 months (95% CI, 10.6 months to NE). In patients who had serosal effusions at baseline, the median PFS was 4.8 months (IQR, 3.5-11.7 months), and the median OS was 10.6 months (IQR, 5.1-13.0 months), compared with 47.8 months (IQR, 11.4 months to NE) and 47.8 months (IQR, 15.7 months to NE), respectively, in patients without serosal effusions. Overall, sirolimus was fairly well tolerated, with 10 patients reporting irregular menstruation/ovary disfunction.

Conclusions: The current results confirm that sirolimus is active in EHE, leading to prolonged stabilization in most patients who present without serosal effusions. Serosal effusions are confirmed as an unfavorable prognostic sign associated with short survival, and sirolimus displays limited activity in this subgroup.

Keywords: chemotherapy; epithelioid hemangioendothelioma; metastasis; prognosis; sarcoma; serosal effusion; sirolimus.

© 2020 American Cancer Society.

References

    1. Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press; 2013.
    1. Sardaro A, Bardoscia L, Petruzzelli MF, Portaluri M. Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. Oncol Rev. 2014;8:259.
    1. Lau K, Massad M, Pollak C, et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest. 2011;140:1312-1318.
    1. Rosenbaum E, Jadeja B, Xu B, et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol. 2020;33:591-602.
    1. Lamar JM, Nehru VM, Weinberg G. Epithelioid hemangioendothelioma as a model of YAP/TAZ-driven cancer: insights from a rare fusion sarcoma. Cancers (Basel). 2018;10:229.
    1. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50:644-653.
    1. Suurmeijer AJH, Dickson BC, Swanson D, Sung YS, Zhang L, Antonescu CR. Variant WWTR1 gene fusions in epithelioid hemangioendothelioma-a genetic subset associated with cardiac involvement. Genes Chromosomes Cancer. 2020;59:389-395.
    1. Kitaichi M, Nagai S, Nishimura K, et al. Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. Eur Respir J. 1998;12:89-96.
    1. Yousaf N, Maruzzo M, Judson I, Al-Muderis O, Fisher C, Benson C. Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience. Anticancer Res. 2015;35:473-480.
    1. Shiba S, Imaoka H, Shioji K, et al. Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study. BMC Cancer. 2018;18:993.
    1. Noh OK, Kim SS, Yang MJ, et al. Treatment and prognosis of hepatic epithelioid hemangioendothelioma based on SEER data analysis from 1973 to 2014. Hepatobiliary Pancreat Dis Int. 2020;19:29-35.
    1. Cioffi A, Italiano A, Penel N, et al. Metastatic epithelioid hemangioendothelioma (EHE): role of systemic therapy and survival [abstract]. J Clin Oncol. 2011;29(15 suppl):10079.
    1. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257-263.
    1. Zheng Z, Wang H, Jiang H, Chen E, Zhang J, Xie X. Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: a case report and literature review. Medicine (Baltimore). 2017;96:e8507.
    1. Semenisty V, Naroditsky I, Keidar Z, Bar-Sela G. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options. BMC Cancer. 2015;15:402.
    1. Chevreau C, Le Cesne A, Ray-Coquard I, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013;119:2639-2644.
    1. Soape MP, Verma R, Payne JD, Wachtel M, Hardwicke F, Cobos E. Treatment of hepatic epithelioid hemangioendothelioma: finding uses for thalidomide in a new era of medicine. Case Rep Gastrointest Med. 2015;2015:326795.
    1. Radzikowska E, Szczepulska-Wojcik E, Chabowski M, Oniszh K, Langfort R, Roszkowski K. Pulmonary epithelioid haemangioendothelioma-interferon 2-alpha treatment-case report. Pneumonol Alergol Pol. 2008;76:281-285.
    1. Stacchiotti S, Provenzano S, Dagrada G, et al. Sirolimus in advanced epithelioid hemangioendothelioma: a retrospective case-series analysis from the Italian Rare Cancer Network database. Ann Surg Oncol. 2016;23:2735-2744.
    1. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40:573-585.
    1. Falger JC, Mueller T, Arbeiter K, et al. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant. 2006;10:565-569.
    1. Lazarus A, Fuhrer G, Malekiani C, McKay S, Thurber J. Primary pleural epithelioid hemangioendothelioma (EHE)-two cases and review of the literature. Clin Respir J. 2011;5:e1-e5.
    1. Kollar A, Jones RL, Stacchiotti S, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol. 2017;56:88-92.
    1. Engel ER, Cournoyer E, Adams DM, Stapleton S. A retrospective review of the use of sirolimus for pediatric patients with epithelioid hemangioendothelioma (EHE). J Pediatr Hematol Oncol. Published online November 8, 2019. doi:10.1097/MPH.0000000000001643
    1. Anderson T, Zhang L, Hameed M, Rusch V, Travis WD, Antonescu CR. Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. Am J Surg Pathol. 2015;39:132-139.
    1. Amin RMS, Hiroshima K, Kokubo T, et al. Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report. Respirology. 2006;11:818-825.
    1. Armato SG 3rd, Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (version 1.1). J Thorac Oncol. 2018;13:1012-1021.
    1. Liu K, Xie P, Peng W, Zhou Z. The computed tomographic findings of pulmonary epithelioid hemangioendothelioma. Radiol Med. 2014;119:705-713.
    1. Gordillo GM, Onat D, Stockinger M, et al. A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation. Am J Physiol Cell Physiol. 2004;287:C866-C873.
    1. Cohen EE, Wu K, Hartford C, et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012;18:4785-4793.
    1. Hansen CG, Ng YLD, Lam WLM, Plouffe SW, Guan KL. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. Cell Res. 2015;25:1299-1313.
    1. Braun M, Young J, Reiner CS, Poster D, Wuthrich RP, Serra AL. Ovarian toxicity from sirolimus. N Engl J Med. 2012;366:1062-1064.
    1. Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:820-829.
    1. Sparagana S, Franz DN, Krueger DA, et al. Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. PLoS One. 2017;12:e0186235.
    1. Bachmann F, Glander P, Budde K, Bachmann C. High incidence of ovarian cysts in women receiving mTOR inhibitors after renal transplantation. J Womens Health (Larchmt). 2018;27:394-398.
    1. Alfadhli E, Koh A, Albaker W, et al. High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation. Transpl Int. 2009;22:622-625.
    1. Cure P, Pileggi A, Froud T, et al. Alterations of the female reproductive system in recipients of islet grafts. Transplantation. 2004;78:1576-1581.
    1. Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant. 2004;4:130-131.
    1. Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int. 2007;20:305-311.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa